Journal article

High-visibility warning labels on paracetamol-containing products do not prevent supratherapeutic ingestion in a simulated scenario

Joe-Anthony Rotella, Anselm Wong, Jocelyn Howell, Amy Robotham, Shaun Greene

CLINICAL TOXICOLOGY | TAYLOR & FRANCIS LTD | Published : 2015

Abstract

CONTEXT: In Australia, legislation requires medication containing paracetamol display warning of co-administration with other paracetamol products, and safe maximum daily dosing (4 g). Labelling style, size and visibility differ, potentially leading possible supratherapeutic misadventure. OBJECTIVE: We studied the likelihood of participants exceeding the recommended dose of paracetamol using products with standard packaging versus products labelled with one of two additional warning labels. METHODS: This was a pilot prospective, observational study, conducted from May 2013 to July 2014. Participants undertook a structured interview to create a simulated 24-h scenario in which they chose from..

View full abstract

University of Melbourne Researchers